Biostar Pharmaceuticals, Inc. develops, manufactures, and markets over-the-counter (OTC) and prescription pharmaceutical products for various diseases and conditions in the People's Republic of China. The company principally offers Xin Ao Xing Oleanolic Acid capsule, an OTC medicine for chronic hepatitis B. It also provides 12 other OTC products and 17 prescription-based pharmaceuticals. The company's OTC products also comprise Ganwang compound paracetamol and amantadine hydrochloride capsule for the relief of common cold, runny nose, sore throat, headache, and fever; Tianqi Dysmenorrhea capsule, a traditional Chinese medicine used for pain and other symptoms associated with menstruation; Deafness Tongqiao pills for hepatobiliary Huosheng, head swelling, deafness and tinnitus, ear pus, dry stool, and urine-yellow; Wenweishu capsules for the treatment of chronic gastritis and pain of epigastric cold; Zhitongtougu ointment for treating joint pain, swelling, tenderness, or dysfunction; and Chuzhang Zehaifu tablets for cataract. Its prescription pharmaceutical products include Danshen granules; Taohuasan pediatric medicines; Jingang tablets; Danxiang Rhinitis tablets; Yanlixiao capsules; Piracetam tablets; Huangyangning tablets; Hyperthyroidism capsules; Fosfomycin Calcium capsules; Qianlietong capsules; Yituo Erythromycin particles; Danshen tablets; Muxiang Shunqi pills; Sifangwei capsules; and Aspirin Enteric-coated tablets. The company also operates a Website that serves as Internet-based China Hepatitis Internet hospital, which offers HBV patients with information on HBV and treatment options, as well as methods to purchase HBV medicines. Biostar Pharmaceuticals, Inc. sells its products through distributors and a network of sales people in approximately 28 provinces. The company was incorporated in 2007 and is headquartered in Xianyang, the People's Republic of China.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BSPM
CUSIPN/A
Phone011-86-29-3368-6638
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E Ratio3.33
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.38 million
Price / Sales2.61
Cash FlowN/A
Price / CashN/A
Book Value$13.98 per share
Price / Book0.17
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees200
Outstanding Shares2,640,000
Market Cap$6.14
Biostar Pharmaceuticals (NASDAQ:BSPM) Frequently Asked Questions
What is Biostar Pharmaceuticals' stock symbol?
Biostar Pharmaceuticals trades on the NASDAQ under the ticker symbol "BSPM."
How were Biostar Pharmaceuticals' earnings last quarter?
Biostar Pharmaceuticals Inc (NASDAQ:BSPM) issued its earnings results on Wednesday, November, 15th. The company reported ($0.50) EPS for the quarter. During the same quarter in the prior year, the company posted ($3.12) EPS. View Biostar Pharmaceuticals' Earnings History.
What is the consensus analysts' recommendation for Biostar Pharmaceuticals?
0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biostar Pharmaceuticals in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."
Who are some of Biostar Pharmaceuticals' key competitors?
Some companies that are related to Biostar Pharmaceuticals include RegeneRx Biopharmaceuticals (RGRX), Eyegate Pharmaceuticals (EYEG), Nuvo Pharmaceuticals (NRIFF), Diffusion Pharmaceuticals (DFFN), ESSA Pharma (EPIX), Pulmatrix (PULM), IntelliPharmaCeutics Intl (IPCI), Midatech Pharma (MTP), Egalet (EGLT), Prana Biotechnology (PRAN), Aralez Pharmaceuticals (ARLZ), Innovus Pharmaceuticals (INNV), Agile Therapeutics (AGRX), Kaya (KAYS) and MusclePharm (MSLP).
Who are Biostar Pharmaceuticals' key executives?
Biostar Pharmaceuticals' management team includes the folowing people:
- Mr. Ronghua Wang, Chairman, CEO & Pres (Age 62)
- Mr. Zhenghong Wang, Chief Operating Officer (Age 38)
- Ms. Xiaojuan Zhai, Chief Financial Officer (Age 29)
- Prof. Xiaohui Zheng, Chief Scientist (Age 50)
- Ms. Shuang Gong, Director of Admin. & Sec. of Board (Age 51)
Has Biostar Pharmaceuticals been receiving favorable news coverage?
News stories about BSPM stock have been trending somewhat negative on Monday, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Biostar Pharmaceuticals earned a news impact score of -0.01 on Accern's scale. They also gave news articles about the company an impact score of 45.76 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of Biostar Pharmaceuticals?
Shares of BSPM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biostar Pharmaceuticals' stock price today?
One share of BSPM stock can currently be purchased for approximately $2.35.
How big of a company is Biostar Pharmaceuticals?
Biostar Pharmaceuticals has a market capitalization of $6.14 million and generates $2.38 million in revenue each year. Biostar Pharmaceuticals employs 200 workers across the globe.
How can I contact Biostar Pharmaceuticals?
Biostar Pharmaceuticals' mailing address is NO. 588 SHIJI XI AVENUE, XIANYANG SHAANXI PROVINCE F4, 712046. The company can be reached via phone at 011-86-29-3368-6638.
MarketBeat Community Rating for Biostar Pharmaceuticals (NASDAQ BSPM)
MarketBeat's community ratings are surveys of what our community members think about Biostar Pharmaceuticals and other stocks. Vote "Outperform" if you believe BSPM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BSPM will underperform the S&P 500 over the long term. You may vote once every thirty days.
